Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bradley A. Hauser
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 10
- Beta
- -1.30
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -35.52
Financials
Net Income
$-2.73MEBITDA
$-2.73MFree Cash Flow
$-3.54MEPS (diluted)
$-5.02Shares Outstanding (diluted)
543.7K-42.3%Operating Expenses
$2.77MCash & Debt
$3.46MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-16.71M | $-48.64 |
| 2025 | $0.00 | $-11.41M | $-135.65 |
| 2024 | $0.00 | $-15.43M | $-343.78 |
| 2023 | $0.00 | $-1.99M | $-44.48 |
| 2022 | $0.00 | $-13.33M | $-286.98 |
Valuation
AMIXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·8d ago·Positive
Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
…x's transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, taking place Septemb…
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery New patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain
View source ↗
Earnings
Wed, Nov 11(in 4 weeks)
Consensus estimate $-6.20 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-5.02 vs $-6.40beat
- Thu, Jun 4$-4.83 vs $-4.83beat
- Thu, Feb 12$-7.56 vs $-7.56beat
- Fri, Nov 14$-28.98 vs $-31.50beat
- Wed, Aug 13$-22.47 vs $-18.59miss
- Thu, May 29$-38.53 vs $-25.93miss
Estimates and results for AMIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMIX officers and directors.
- Bought
- $1k
- Sold
- —
2 trades
0 trades
- Robins David Andrewbought
- Biostar Ventures Iii, L.p.bought
31 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AMIX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.